Last reviewed · How we verify

Amlodipine plus Hydrochlorothiazide

University of Abuja · FDA-approved active Small molecule

Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure.

Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure. Used for Hypertension.

At a glance

Generic nameAmlodipine plus Hydrochlorothiazide
SponsorUniversity of Abuja
Drug classCalcium channel blocker + thiazide diuretic combination
TargetL-type voltage-gated calcium channel (amlodipine); sodium-chloride cotransporter (hydrochlorothiazide)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, promoting natriuresis and reducing circulating blood volume. The combination provides complementary antihypertensive effects through different mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: